Understanding the etiology of infectious or chronic inflammatory diseases, when used in conjunction with clinical information and other laboratory testing
Research studies in which an assessment of cytokine responses is needed
Bead-Based Multiplex Immunoassay
Cytokine storm
Cytokines
Tumor necrosis factor alpha
Interleukin-6
Interferon Beta
Interleukin-10
CCL2/MCP-1
Monocyte Chemoattractant Protein-1
Interleukin-1 beta
IL-1B/IL-1F2
Interferon gamma
CCL3/MIP-1A
Macrophage Inflammatory Protein-1A
Granulocyte Macrophage Colony Stimulating Factor
CD25/IL-2 RA
Interleukin-2 Soluble Receptor Alpha
Interferon alpha-2a
IL-18/IL-1F4
Interleukin-18
Plasma EDTA
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Lavender-top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions:
1. Immediately after specimen collection, place the tube on wet ice.
2. Centrifuge at 4 degrees C, 1500 x g for 10 minutes.
3. Aliquot plasma into plastic vial.
4. Freeze specimen within 2 hours of collection.
0.3 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Heat-treated specimen | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma EDTA | Frozen | 21 days |
Understanding the etiology of infectious or chronic inflammatory diseases, when used in conjunction with clinical information and other laboratory testing
Research studies in which an assessment of cytokine responses is needed
Cytokines are important mediators of cell-to-cell communication within the innate and adaptive immune systems. The expression of most cytokines is highly regulated and generally occurs in response to foreign or self-antigenic stimulation. The functions of cytokines are extremely varied, with many cytokines also displaying pleiotropic effects, depending on their cellular target. Some cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-1 beta, IL-6, interferon (IFN)-alpha and beta, IL-10, and IL-18 are particularly important in the innate immune response. For example, TNF, IL-1 beta, and IL-6 induce expression of acute phase proteins in the liver. TNF and IL-1 beta also lead to endothelial activation and are critical regulators of the hypothalamus, which can result in elevated body temperature. IL-6, in comparison, is a bridge to the adaptive immune response, by acting on B cells to induce proliferation. In contrast, IFN-alpha and IFN-beta (members of the type I IFN family) are key components of the innate immune response to viral infections. IFN-gamma, which is a type II IFN, has roles in both the innate and adaptive immune responses, including macrophage activation, induction of B-cell isotype switching, and T helper type 1 cell differentiation. Other cytokines, such as monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 alpha, are categorized as chemokines because they function primarily to attract leukocytes to the site of inflammation. Further, some cytokines act on hematopoietic stem cells to induce differentiation of various leukocytes. For example, granulocyte-monocyte colony stimulating factor induces myeloid progenitor cells to differentiate into neutrophils and monocytes. Lastly, for some cytokines, soluble forms of the receptor can be found in the peripheral circulation. The IL-2 soluble receptor is produced from proteolytic cleavage of the membrane-bound receptor, which occurs during T-cell activation. As a group, cytokines and their receptors represent a highly complex and critical regulator of a normal immune response.
Tumor necrosis factor: <10.0 pg/mL
Interleukin (IL)-6: <5.0 pg/mL
Interferon (IFN)-beta: <20.0 pg/mL
IL-10: <7.0 pg/mL
Monocyte chemoattractant protein-1: < or =198 pg/mL
IL-1 beta: <20.0 pg/mL
IFN-gamma: <60.0 pg/mL
Macrophage inflammatory protein-1 alpha: <220 pg/mL
Granulocyte-monocyte colony stimulating factor: <15.0 pg/mL
IL-2 receptor alpha soluble: < or =959 pg/mL
IFN-alpha: <20.0 pg/mL
IL-18: < or =468 pg/mL
Elevated cytokine concentrations could be consistent with the presence of infection or other inflammatory process.
Results from cytokine testing should not be used to establish or exclude a specific diagnosis.
Cytokine testing should only be used in conjunction with clinical information and other laboratory testing as part of a patient’s overall assessment.
Normal concentrations of cytokines do not exclude the possibility of infection or other inflammatory condition.
Cytokine concentrations could be affected by immunomodulatory agents.
1. Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11(2):R49. doi:10.1186/cc5783
2. Milman N, Karsh J, Booth RA. Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem. 2010;43(16-17):1309-1314. doi:10.1016/j.clinbiochem.2010.07.012
3. Teijara JR. Type I interferons in viral control and immune regulation. Curr Opin Virol. 2016;16:31-40. doi:10.1016/j.coviro.2016.01.001
4. Tisoncki JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2010;76(1):16-32. doi:10.1128/MMBR.05015-11
5. Garcia Borrega J, Godel P, Ruger MA, et al. In the eye of the storm: Immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019;3(2):e191. doi:10.1097/HS9.0000000000000191
Analyte-specific antibodies are pre-coated onto color-coded magnetic microparticles. Samples are diluted 1:2 in a mixing plate and then standards, samples, and microparticles are pipetted into wells and the immobilized antibodies capture the analytes of interest. Unbound substances are washed away while the magnetic microparticles are immobilized. Next, a biotinylated analyte specific antibody cocktail is added to each well. Following a wash to remove any unbound biotinylated antibody, streptavidin-phycoerythrin conjugate (Streptavidin-PE), is added to each well. After removal of unbound Streptavidin-PE and resuspension of the microparticles in buffer, the plate is analyzed using a Luminex FLEXMAP 3D analyzer. A charged-coupled device camera captures an image of each well and data reduction is performed using the XPONENT software.(Unpublished Mayo method)
Wednesday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
83520 x 10
83529
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
CYPAN | Cytokine Panel, P | 82335-1 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
610307 | TNF | 3074-2 |
610308 | IL-6 | 26881-3 |
610309 | IFN-beta | 97051-7 |
610310 | IL-10 | 26848-2 |
610311 | MCP-1 | 97052-5 |
610312 | IL-1 beta | 13629-1 |
610313 | IFN-gamma | 27415-9 |
610314 | MIP-1 alpha | 97053-3 |
610315 | GM-CSF | 97054-1 |
610316 | IL-2 receptor alpha soluble | 76039-7 |
610317 | IFN-alpha | 33820-2 |
610318 | IL-18 | 33823-6 |
Change Type | Effective Date |
---|---|
Test Status - Test Delay | 2024-07-23 |